Metmorfin: Alternative Use in Treatment of Polycystic Ovary Syndrome

Historically, Metformin has been used in the treatment of Type 2 diabetes mellitus. Recently, however, Metformin has been medically applied as an alternative form of treatment into other health disorders, specifically in polycystic ovary syndrome. For a women suffering from polycystic ovary syndrome, finding a remedy to improve symptoms, without the need for surgery, may provide for a more healthy response in female reproductive disorders. As a result, many more women, in collaboration with their gynecologists, are turning to Metmorfin as an alternative first line defense in the treatment of polycystic ovary syndrome.

Polycystic ovary syndrome is a term used to describe a condition in which a woman's ovaries abnormally ovulate leading to absent or irregular menstrual cycles. While the condition is prevalent in nearly 10 out of every 100 women, it has continued to be a gynecological disorder of mass confusion among the health care industry. While many women suffer from polycystic ovary syndrome, a small portion will experience pain and health complications arising out of the gynecological complication. It is this group of women who are now exploring options into the use of Metmorfin in treating polycystic ovary syndrome.

Associated with insulin resistance, medical technology has turned focus, in the research of polycystic ovary syndrome, to methods commonly used in the treatment of insulin dependent diabetics. One such treatment, in the form of a prescription drug known as Metmorfin, may provide a viable treatment alternative to women suffering from this painful and life altering gynecological disorder. So, what is Metmorfin?

Metmorfin, an FDA approved drug under the brand name of Glucophage, is an antidiabetic drug which mimics the actions of insulin in Type 2 diabetic patients who are unable to utilize naturally produced insulin in regulating blood glucose levels. Because women with polycystic ovary syndrome have shown to also suffer from co morbid complications associated with elevated blood glucose levels, the use of Metmorfin has become increasingly common in an effort to regulate this same blood glucose and, therefore, reduce the complications and prevalence of polycystic ovary syndrome.

In addition to the use of Metmorfin, to treat polycystic ovary syndrome, gynecologist generally recommend that women obtain nutritional counseling by a licensed dietician in order to control, to some extent, the types and quantity of calorie intake each day. Because maintaining energy and metabolism is crucial to the success of Metmorfin use, nutritional guidelines must be followed while treating for polycystic ovary syndrome in this non-FDA approved method.

Dosing of Metmorfin, in the treatment of polycystic ovary syndrome, most commonly involves the use of extended release tablets of the blood glucose regulating prescription drug. These extended release Metmorfin tablets are generally prescribed at 500 milligrams per evening, with a meal, with adjustments in 500 milligram increments per week until the right level of control over blood glucose is achieved. Following use of Metmorfin, over several months, a woman will begin to notice a significant change in the symptoms commonly associated with polycystic ovary syndrome.

As with most FDA approved drugs, the use of Metmorfin, in the treatment of polycystic ovary syndrome, does not come without side effects. While not approved for treatment, by the FDA, of polycystic ovary syndrome, data reports with regard to the complications in these polycystic ovary syndrome female patients is conflicting. However, at face value, women using Metmorfin, in treating polycystic ovary syndrome, will commonly experience improvement in symptoms with little to few sides effects; namely, muscle pain, cramping and stomach upset, including diarrhea. Additionally, when using Metmorfin to treat polycystic ovary syndrome, there is a risk of developing hypoglycemia in which a condition develops leading to a drop in blood glucose below that which is normal resulting in complications such as syncope, drowsiness, irregular heart rate, confusion and cold sweats. When symptoms of hypoglycemia are significant, consultation with the gynecologist should occur immediately so as to determine what, if any, modifications to diet and prescription medication usage should take place.

As with any complication of the female reproductive system, obtaining early diagnosis and treatment is the key to achieving optimal health and treatment outcomes. While Metmorfin, also known as Glucophage, is not FDA approved for the treatment of polycystic ovary syndrome, it has shown great results in providing relief and improvement in the gynecological symptoms and overall improvement in the anovulation associated with polycystic ovary syndrome.